Updates are available Correction dated 2021-10-08
Click to view Correction: https://doi.org/10.1007/s10549-021-06409-y
-
Authors
Pondé, Noam http://orcid.org/0000-0003-4016-0407
Agbor-Tarh, Dominique
Dal Lago, Lissandra
Korde, Larissa A.
Hilbers, Florentine
Jackisch, Christian
Werner, Olena
Gelber, Richard D.
Jatoi, Aminah
Dueck, Amylou C.
Moreno-Aspitia, Alvaro
Sotiriou, Christos
de Azambuja, Evandro
Piccart, Martine
-
Funding
Funding for this research was provided by:
Novartis
GlaxoSmithKline
- License Information
-
More Information
Article History
Received: 28 January 2020
Accepted: 1 September 2020
First Online: 19 September 2020
Change Date: 8 October 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s10549-021-06409-y
Compliance with ethical standards
:
: Dr Noam Pondé reports he has received fees from Novartis, Lilly, AstraZeneca and Roche. He has received travel grants from Novartis, AstraZeneca and Lilly. Florentine Hilbers reports that her institution has received research grants to fund the ALTTO trial from GSK and Novartis. Christian Jackisch reports grants and fees from Roche, Novartis, and AstraZeneca. Olena Werner is an employee of Novartis. Dr. Richard D. Gelber reports that his institution received grants for partial support for his salary from Novartis, Roche, Merck, Pfizer, AstraZeneca, Celgene, Ipsen, and Ferring. Evandro de Azambuja reports honoraria and advisory board from Roche/GNE, Novartis and SeaGen, travel grants from Roche/GNE and GSK/Novartis and research grant to my institution from Roche/GNE, Astra-Zeneca, GSK/Novartis and Servier. Martine Piccart is a board member for Oncolytics and Radius. She has received honoraria from AstraZeneca, Camel-IDS, Crescendo Biologics, Debiopharm, G1 Therapeutics, Genentech, Huya, Immunomedics, Lilly, Menarini, MSD, Novartis, Odonate, Oncolytics, Periphagen, Pfizer, Roche PharmaMar, and Seattle Genetics. Her institute has received research grants from AstraZeneca, Lilly, MSD, Novartis, Pfizer, Radius, Roche-Genentech, Servier and Synthon. Dominique Agbor-Tarh, Lissandra Dal Lago, Larissa A. Korde, Aminah Jatoi, Amylou C. Dueck, Alvaro Moreno-Aspitia and Christos Sotiriou report no conflicts of interest.
